Bioavailability effect of methylprednisolone by polymeric micelles

Ching Lin Chen, Shwu Fen Chang, Daniel Lee, Lang Yo Yang, Yi-Hsuan Lee, Chung-Yi Hsu, Shwu Jiuan Lin, Jiahorng Liaw

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Purpose. To investigate the effect of PEO-PPO-PEO polymeric micelles (PM) formulation on the bioavailability of methylprednisolone (MP), a treatment of spinal cord injury (SCI), to the blood and spinal cord (SC) of rabbits. Methods. The characteristic of MP formulated with PM (MP/PM) was evaluated by critical micelles concentration (CMC), dynamic light scattering (DLS), atomic force microscopy (AFM) and in vitro kinetic release measurements. HPLC was used to analyze the MP disposition in plasma and SC of rabbits receiving single dose intravenous administration. After MP/PM delivery, the mRNA and protein levels of anti-apoptotic marker, Bcl-xL, were monitored by Reverse Transcription -Real-Time -Polymerase Chain Reaction (RT-qPCR) and Western blotting analysis, respectively. Results. At a concentration of 0.1% and at 25°C, PEO-PPO-PEO copolymers formed micelles shown by fluorescence probe, DLS and solubility test. The size of the MP/PM was in an average of 60 nm with a single, rounded shape detected under AFM. Being formulated with 6% PM, MP had higher solubility (219.6±3.6 μg/ml) and release rate (11.1±0.4 ng min1/2) at 37°C. After intravenously administrated with single dose of 1 mg/kg of MP/PM to rabbits, higher levels of MP in plasma and SC were detected compared to animals receiving an equal dose of MP, analyzed by HPLC. PM formulation markedly increased (7-fold) the plasma half-lives (t 1/2) of MP (from 76.1±8.0 to 514.3±70.0 min). In addition, the SC t 1/2 of MP/PM also increased from 278 to 528 min. In SC, the mRNA level of Bcl-xL increased 4-fold in animals receiving MP/PM compared to that with MP alone at 7 h post-administration. Similar elevated Bcl-xL protein was also detected upon MP/PM administration compared to MP. Conclusions. PM vehicle was able to deliver MP to improve its pharmacokinetic profile in plasma and SC with higher expression of anti-apoptotic Bcl-xL at both mRNA and protein levels.

Original languageEnglish
Pages (from-to)39-47
Number of pages9
JournalPharmaceutical Research
Volume25
Issue number1
DOIs
Publication statusPublished - Jan 2008

Fingerprint

Methylprednisolone
Micelles
Biological Availability
Spinal Cord
Plasmas
Atomic Force Microscopy
Dynamic light scattering
Rabbits
Solubility
Messenger RNA
Atomic force microscopy
Animals
High Pressure Liquid Chromatography
Apoptosis Regulatory Proteins
Proteins
Pharmacokinetics
Critical micelle concentration
Polymerase chain reaction
Transcription
Spinal Cord Injuries

Keywords

  • Bcl-x
  • Bioavailability
  • Methylprednisolone
  • PM
  • Spinal cord

ASJC Scopus subject areas

  • Chemistry(all)
  • Pharmaceutical Science
  • Pharmacology

Cite this

Bioavailability effect of methylprednisolone by polymeric micelles. / Chen, Ching Lin; Chang, Shwu Fen; Lee, Daniel; Yang, Lang Yo; Lee, Yi-Hsuan; Hsu, Chung-Yi; Lin, Shwu Jiuan; Liaw, Jiahorng.

In: Pharmaceutical Research, Vol. 25, No. 1, 01.2008, p. 39-47.

Research output: Contribution to journalArticle

Chen, Ching Lin ; Chang, Shwu Fen ; Lee, Daniel ; Yang, Lang Yo ; Lee, Yi-Hsuan ; Hsu, Chung-Yi ; Lin, Shwu Jiuan ; Liaw, Jiahorng. / Bioavailability effect of methylprednisolone by polymeric micelles. In: Pharmaceutical Research. 2008 ; Vol. 25, No. 1. pp. 39-47.
@article{8ca87a2690fd408fa3d984912500e5c8,
title = "Bioavailability effect of methylprednisolone by polymeric micelles",
abstract = "Purpose. To investigate the effect of PEO-PPO-PEO polymeric micelles (PM) formulation on the bioavailability of methylprednisolone (MP), a treatment of spinal cord injury (SCI), to the blood and spinal cord (SC) of rabbits. Methods. The characteristic of MP formulated with PM (MP/PM) was evaluated by critical micelles concentration (CMC), dynamic light scattering (DLS), atomic force microscopy (AFM) and in vitro kinetic release measurements. HPLC was used to analyze the MP disposition in plasma and SC of rabbits receiving single dose intravenous administration. After MP/PM delivery, the mRNA and protein levels of anti-apoptotic marker, Bcl-xL, were monitored by Reverse Transcription -Real-Time -Polymerase Chain Reaction (RT-qPCR) and Western blotting analysis, respectively. Results. At a concentration of 0.1{\%} and at 25°C, PEO-PPO-PEO copolymers formed micelles shown by fluorescence probe, DLS and solubility test. The size of the MP/PM was in an average of 60 nm with a single, rounded shape detected under AFM. Being formulated with 6{\%} PM, MP had higher solubility (219.6±3.6 μg/ml) and release rate (11.1±0.4 ng min1/2) at 37°C. After intravenously administrated with single dose of 1 mg/kg of MP/PM to rabbits, higher levels of MP in plasma and SC were detected compared to animals receiving an equal dose of MP, analyzed by HPLC. PM formulation markedly increased (7-fold) the plasma half-lives (t 1/2) of MP (from 76.1±8.0 to 514.3±70.0 min). In addition, the SC t 1/2 of MP/PM also increased from 278 to 528 min. In SC, the mRNA level of Bcl-xL increased 4-fold in animals receiving MP/PM compared to that with MP alone at 7 h post-administration. Similar elevated Bcl-xL protein was also detected upon MP/PM administration compared to MP. Conclusions. PM vehicle was able to deliver MP to improve its pharmacokinetic profile in plasma and SC with higher expression of anti-apoptotic Bcl-xL at both mRNA and protein levels.",
keywords = "Bcl-x, Bioavailability, Methylprednisolone, PM, Spinal cord",
author = "Chen, {Ching Lin} and Chang, {Shwu Fen} and Daniel Lee and Yang, {Lang Yo} and Yi-Hsuan Lee and Chung-Yi Hsu and Lin, {Shwu Jiuan} and Jiahorng Liaw",
year = "2008",
month = "1",
doi = "10.1007/s11095-007-9484-0",
language = "English",
volume = "25",
pages = "39--47",
journal = "Pharmaceutical Research",
issn = "0724-8741",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Bioavailability effect of methylprednisolone by polymeric micelles

AU - Chen, Ching Lin

AU - Chang, Shwu Fen

AU - Lee, Daniel

AU - Yang, Lang Yo

AU - Lee, Yi-Hsuan

AU - Hsu, Chung-Yi

AU - Lin, Shwu Jiuan

AU - Liaw, Jiahorng

PY - 2008/1

Y1 - 2008/1

N2 - Purpose. To investigate the effect of PEO-PPO-PEO polymeric micelles (PM) formulation on the bioavailability of methylprednisolone (MP), a treatment of spinal cord injury (SCI), to the blood and spinal cord (SC) of rabbits. Methods. The characteristic of MP formulated with PM (MP/PM) was evaluated by critical micelles concentration (CMC), dynamic light scattering (DLS), atomic force microscopy (AFM) and in vitro kinetic release measurements. HPLC was used to analyze the MP disposition in plasma and SC of rabbits receiving single dose intravenous administration. After MP/PM delivery, the mRNA and protein levels of anti-apoptotic marker, Bcl-xL, were monitored by Reverse Transcription -Real-Time -Polymerase Chain Reaction (RT-qPCR) and Western blotting analysis, respectively. Results. At a concentration of 0.1% and at 25°C, PEO-PPO-PEO copolymers formed micelles shown by fluorescence probe, DLS and solubility test. The size of the MP/PM was in an average of 60 nm with a single, rounded shape detected under AFM. Being formulated with 6% PM, MP had higher solubility (219.6±3.6 μg/ml) and release rate (11.1±0.4 ng min1/2) at 37°C. After intravenously administrated with single dose of 1 mg/kg of MP/PM to rabbits, higher levels of MP in plasma and SC were detected compared to animals receiving an equal dose of MP, analyzed by HPLC. PM formulation markedly increased (7-fold) the plasma half-lives (t 1/2) of MP (from 76.1±8.0 to 514.3±70.0 min). In addition, the SC t 1/2 of MP/PM also increased from 278 to 528 min. In SC, the mRNA level of Bcl-xL increased 4-fold in animals receiving MP/PM compared to that with MP alone at 7 h post-administration. Similar elevated Bcl-xL protein was also detected upon MP/PM administration compared to MP. Conclusions. PM vehicle was able to deliver MP to improve its pharmacokinetic profile in plasma and SC with higher expression of anti-apoptotic Bcl-xL at both mRNA and protein levels.

AB - Purpose. To investigate the effect of PEO-PPO-PEO polymeric micelles (PM) formulation on the bioavailability of methylprednisolone (MP), a treatment of spinal cord injury (SCI), to the blood and spinal cord (SC) of rabbits. Methods. The characteristic of MP formulated with PM (MP/PM) was evaluated by critical micelles concentration (CMC), dynamic light scattering (DLS), atomic force microscopy (AFM) and in vitro kinetic release measurements. HPLC was used to analyze the MP disposition in plasma and SC of rabbits receiving single dose intravenous administration. After MP/PM delivery, the mRNA and protein levels of anti-apoptotic marker, Bcl-xL, were monitored by Reverse Transcription -Real-Time -Polymerase Chain Reaction (RT-qPCR) and Western blotting analysis, respectively. Results. At a concentration of 0.1% and at 25°C, PEO-PPO-PEO copolymers formed micelles shown by fluorescence probe, DLS and solubility test. The size of the MP/PM was in an average of 60 nm with a single, rounded shape detected under AFM. Being formulated with 6% PM, MP had higher solubility (219.6±3.6 μg/ml) and release rate (11.1±0.4 ng min1/2) at 37°C. After intravenously administrated with single dose of 1 mg/kg of MP/PM to rabbits, higher levels of MP in plasma and SC were detected compared to animals receiving an equal dose of MP, analyzed by HPLC. PM formulation markedly increased (7-fold) the plasma half-lives (t 1/2) of MP (from 76.1±8.0 to 514.3±70.0 min). In addition, the SC t 1/2 of MP/PM also increased from 278 to 528 min. In SC, the mRNA level of Bcl-xL increased 4-fold in animals receiving MP/PM compared to that with MP alone at 7 h post-administration. Similar elevated Bcl-xL protein was also detected upon MP/PM administration compared to MP. Conclusions. PM vehicle was able to deliver MP to improve its pharmacokinetic profile in plasma and SC with higher expression of anti-apoptotic Bcl-xL at both mRNA and protein levels.

KW - Bcl-x

KW - Bioavailability

KW - Methylprednisolone

KW - PM

KW - Spinal cord

UR - http://www.scopus.com/inward/record.url?scp=38049139283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38049139283&partnerID=8YFLogxK

U2 - 10.1007/s11095-007-9484-0

DO - 10.1007/s11095-007-9484-0

M3 - Article

VL - 25

SP - 39

EP - 47

JO - Pharmaceutical Research

JF - Pharmaceutical Research

SN - 0724-8741

IS - 1

ER -